Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bi-4SCAR-CD19/70 CAR-T in B Cell Malignancies
NCT05436496Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B-cell malignancy, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of fourth generation bi-4SCARCD19/70 T cells at 12 weeks. Planned start Jun 2027; status: not yet recruiting.
02
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT05436496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436496.